Cancer Cellular Therapy
Adaptive has partnered* with Genentech, a member of the Roche Group, to develop, manufacture, and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. We are building a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer.
*The completion of the agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to occur in the first quarter of 2019.
Adaptive has partnered with Microsoft to map and decode the human immune system, nature’s most finely tuned diagnostic. The ultimate goal is to develop a universal blood-based diagnostic, so that diseases can be detected in their earliest stages when they can be most effectively treated.
Adaptive works with nearly 100 biopharmaceutical partners in over 150 trials per year across the research and development value chain to incorporate proven immune-driven metrics and screening capabilities into translational analyses, diagnostic tools and drug discovery efforts. We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkers of efficacy or adverse events for later stage trials, and screen for drug candidates that utilize or leverage the acumen of the immune system. In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers, and novel target screening.
Adaptive works with academic investigators, government-sponsored scientific institutions, and cooperative research organizations globally to incorporate immune profiling into high-impact research and clinical trials across disease settings. We work closely with teams on study design, sequencing, data analysis, and publication, with the overall goal of using immune repertoire dynamics to understand disease and host interactions, stratify patient populations, determine potential biomarkers of drug response, and ultimately improve patient outcomes.